Persons with type 1 or type 2 diabetes have a significantly higher fracture risk than age-matched persons without diabetes, attributed to disease-specific deficits in the microarchitecture and material properties of bone tissue. Therefore, independent effects of diabetes drugs on skeletal integrity are vitally important. Studies of incretin-based therapies have shown divergent effects of different agents on fracture risk, including detrimental, beneficial, and neutral effects. The sulfonylurea class of drugs, owing to its hypoglycemic potential, is thought to amplify the risk of fallrelated fractures, particularly in the elderly. Other agents such as the biguanides may, in fact, be osteo-anabolic. In contrast, despite similarly expected anabolic properties of insulin, data suggests that insulin pharmacotherapy itself, particularly in type 2 diabetes, may be a risk factor for fracture, negatively associated with determinants of bone quality and bone strength. Finally, sodium-dependent glucose co-transporter 2 inhibitors have been associated with an increased risk of atypical fractures in select populations, and possibly with an increase in lower extremity amputation with specific SGLT2I drugs. The role of skeletal muscle, as a potential mediator and determinant of bone quality, is also a relevant area of exploration. Currently, data regarding the impact of glucose lowering medications on diabetes-related muscle atrophy is more limited, although preclinical studies suggest that various hypoglycemic agents may have either aggravating (sulfonylureas, glinides) or repairing (thiazolidinediones, biguanides, incretins) effects on skeletal muscle atrophy, thereby influencing bone quality. Hence, the therapeutic efficacy of each hypoglycemic agent must also be evaluated in light of its impact, alone or in combination, on musculoskeletal health, when determining an individualized treatment approach. Moreover, the effect of newer medications (potentially seeking expanded clinical indication into the pediatric age range) on the growing skeleton is largely unknown. Herein, we review the available literature regarding effects of diabetes pharmacotherapy, by drug class and/or by clinical indication, on the musculoskeletal health of persons with diabetes.
The incidence of both type 1 diabetes (T1D) and type 2 diabetes (T2D) is increasing steadily, both in the United States and worldwide. [1] [2] [3] [4] [5] [6] [7] The National Diabetes Statistics report, 2017 (www.cdc.gov/diabetes/pdfs/ data/statistics/national-diabetes-statistics-report.pdf) 8 estimates that as of 2015, 30.3 million people in the US have diabetes (T1D or T2D), with 23.1 million being diagnosed and 7.2 million being undiagnosed;
90% to 95% of these have T2D. In China, where diabetes prevalence is the highest worldwide, an estimated 110 million adults have diabetes. 1 Globally, the International Diabetes Federation estimates that the diabetes pandemic encompasses 8.8% of the global population; and, in 2017, worldwide health care expenditure for diabetes exceeded 800 billion US dollars (www.diabetesatlas.org). 9 The economic burden of diabetes in the United States alone in 2017 has been estimated at $327 billion, both in direct medical care costs and in reduced productivity, representing a 26% inflation-adjusted cost increase from just 5 years earlier.
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While insulin replacement therapy remains the mainstay of therapy for T1D, the expanding armamentarium of medications for treatment of T2D now includes 11 distinct classes of glucose lowering oral or injectable medications, including insulin 11 (Table 1) . Consensus guidelines of the American Diabetes Association and the European Association for the Study of Diabetes 12 recommend a HbA1c treatment target of <7% for most patients withT2D, and multicomponent therapy (along with lifestyle management and diabetes self-management education and support) is indicated if this HbA1c target is not achieved within~3 months from start of treatment. 11 As such, it can be anticipated that a multitude of individuals will, at some point in their lifetime, be exposed to diabetes pharmacotherapy, and very often requiring polypharmacy.
Osteoporosis is also an increasingly common skeletal disorder affecting an estimated 75 million people in Europe, Japan, and the Unites States; it is a condition which increases with aging, and is the predominant contributor to fracture in the elderly (www.
iofbonehealth.org/facts-statistics). 13 Worldwide, osteoporosis contributes annually to >8.9 million fractures. Prevalence rates for osteoporotic vertebral fracture, in particular, are highest in North American and in Asia, geographically mirroring areas that also exhibit a high prevalence of diabetes. 14 At the same time, non-osteoporotic fallrelated fractures are also becoming increasingly common at all ages. 15 Persons with either T1D or T2D are at relatively greater risk for fracture, when compared with age-matched persons without diabetes, potentially compounding these two independent public health concerns. 16, 17 In those with T1D, fracture risk is increased across the lifespan including in childhood, 18 with relative risk for any osteoporotic fracture increasing three-fold, 19 and for hip fracture in particular increasing between four-fold and six-fold. 19, 20 In those with T2D, fracture risk increases with longer duration of diabetes 21 and with poorer glycemic control 22, 23 ; but, for any given femoral neck bone mineral density (BMD) T-score or individual FRAX (World Health Organization Fracture Risk Algorithm) score, fracture risk is greater in those with T2D than in those without diabetes mellitus. 24 Moreover, complications of fracture, such as delayed healing and secondary infection, as well as consequences of fracture, such as prolonged hospitalization and economic burden, are even more detrimental in the diabetic population, compared with the general population. 25, 26 The elevated propensity for fracture in persons with diabetes is not predictable by bone BMD measurements, which are typically only modestly decreased in T1D, 27, 28 and normal or increased in T2D. 29, 30 Instead, elevated fracture risk is attributed to secondary deficits in the microarchitecture 31, 32 and in the material properties of the bone tissue, 33 along with pathophysiological and genetic factors intrinsic to diabetes itself. 32 Variables inherent to both T1D and T2D, including chronic hyperglycemia and glycemic variation, 23 tissue-specific accumulation of advanced glycation end-products (AGEs), 34 ,35 dysregulation of insulin-like growth factor 1 (IGF-1) bioavailability, 36, 37 variable insulin exposure (endogenous or exogenous), enhanced oxidative stress, changes in bone mineral and vitamin D homeostasis, 38 and regional diabetic microvascular disease, undoubtedly all impact the skeletal quality in diabetes. 3 Added to these variables is an increased propensity to falling, whether attributable to acute hypoglycemia, peripheral neuropathy, decreased visual acuity, or postural instability. 39 Finally, the impact of diabetes-related muscle atrophy, as a determinant of both bone quality and individual stability, is relevant to the understanding of skeletal health in these disorders.
A decade ago, diabetes therapy using select thiazolidinedione (TZD) medications was first shown to further increase fracture risk in women with T2D, 40 by accelerating bone loss, 41 and activating osteoclastogenesis. 42 This warning prompted a comprehensive and ongoing evaluation of the effects, both direct and indirect, of diabetes pharmacotherapy on bone health and fracture risk. While the impact of antidiabetes medications on diabetes-related loss of muscle mass has not been as extensively investigated, preclinical studies suggest that various hypoglycemic agents may also have either harmful (sulfonylureas [SUs] , glinides) or beneficial (TZDs, biguanides, incretins) effects on muscle, thereby also influencing bone quality. Hence, when determining individualized treatment strategies for persons with diabetes, the therapeutic efficacy of each hypoglycemic agent must also be evaluated in light of its impact, alone or in combination, on the bone and muscle health of each individual.
The intent of this review is to provide a comprehensive overview of known preclinical and clinical effects of diabetes pharmacotherapy, by drug class and/or by clinical indication, on the musculoskeletal system in diabetes (summarized in Table 2 ). This chapter is considered a comprehensive review and discussion of the literature but is not intended as a clinical management guideline or recommendation. Recommendations regarding the personalized management of persons with both T2D and osteoporosis have recently been published. 43 A similar guideline for the T1D population with osteoporosis has not been established although co-therapy with insulin and various other drugs (SGLT2 inhibitors, amylin mimetics) is on the rise, suggesting that similar recommendations will be needed in the future. Note. A list of all currently FDA-approved glucose lowering medications is provided, according to their drug classification. Drugs are listed alphabetically under each classification heading. Only monocomponent drugs are listed; pre-mixed insulin products or drug class combination products are not included. Abbreviations: T1D, type 1 diabetes; T2D, type 2 diabetes; RpR, ryanodine receptors; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; GIP, gastric inhibitory polypeptide; SGLT2, sodium-dependent glucose co-transporter-2.
*Expanded off-label use. 
Mechanism of action
Insulin is a peptide hormone (~7.5 kD), produced by the β-cell of the pancreas and highly regulated by systemic glucose concentrations.
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Insulin signals primarily through the insulin receptor, a hetero-tetramer made up of two extracellular α-subunits and two transmembrane β-subunits, which is present on most cell-types. 45 Insulin-mediated sig- In T1D, insulin production is reduced and therefore inadequate to control blood glucose levels due to impairment and destruction of pancreatic β-cells. In T2D, insulin production may actually be exaggerated, due to insulin resistance. However, in later stages of T2D, insulin production typically declines as β-cell failure ensues.
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Thus, those with T1D are uniformly treated with insulin, while many individuals with T2D may eventually need to be treated with insulin. 67 Taken together, these in vitro studies suggest that insulin may have broad activity to promote bone formation by regulating various phases of osteoblast maturation and osteoblast metabolism, and by decreasing bone resorption through inhibition of osteoclast activity.
Skeletal effects: In vivo
In rodent models of T1D, wherein significant pancreatic β-cell destruction has occurred and circulating insulin levels are very low to undetect- Debate continues as to whether insulin's ability to improve bone formation in the condition of diabetes is related to its glucose lowering effect and/or to its ability to directly impact osteoblastogenesis and bone formation. Advanced glycation end products (AGEs) are compounds generated through non-enzymatic reactions occurring between sugars and amine residues. In diabetes, where glucose levels are elevated, AGEs are deposited in many tissues, including bone. 74 AGEs are associated with increased bone fragility in diabetes; thus, by lowering glucose levels, insulin may help to decrease accumulation of AGEs in bone. 75, 76 Nevertheless, in vivo evidence also suggests that insulin has a direct effect on bone formation and osteogenesis, irrespective of its effect on glucose metabolism. For instance, several studies in mice have
shown that impaired insulin signaling, via knock-down of the insulin receptor specifically in osteoblast progenitors and mature osteoblasts, results in impaired bone formation, abnormal trabecular architecture, smaller cortices, and increased fragility, dependent on the developmental stage in which the insulin receptor was eliminated and in a sex-specific manner. 56, 77, 78 In other studies, exogenous insulin administration shows a dose-dependent ability to prevent diabetes-related skeletal changes in mice, even though glucose levels remain elevated. 79 Similarly, systemic insulin treatment of diabetic male Wistar rats (alloxan-induced) has been shown to improve bone repair and osteointegration around tibial titanium implants. 80 Further support for a direct action of insulin on osteoblastogenesis in diabetes has come from fracture models in diabetic rodents, which demonstrate that insulin delivered locally to the fracture site results in normalization of mineralization, improved callus bone content, and enhanced biomechanical properties, despite persistent systemic hyperglycemia and systemic hypo-insulinemia. 81 Together these preclinical data support a role for insulin to directly, and possibly indirectly, improve skeletal well-being in the context of active diabetes and persistent hyperglycemia. These findings, however, may be indirectly mediated by the insulinsensitizing and/or glucose-lowering efficacy of metformin in these studies. As shown by Inouye et al, in Goto-Kakizaki (GK) spontaneously diabetic rats treated with metformin, the peri-implant wound healing around oral titanium implants was directly related to the glucose lowering success of the treatment.
148
In contrast, a lack of benefit has been seen in many other studies specifically examining bone regeneration or bone repair. In non-diabetic 189, 190, 198, 203 induction of osteoblast and osteocyte death, 204 increased bone resorption/osteoclast activity, 198, 203 and an increase in adipose content in the bone marrow. 189, 190, 198, 202, 203 In younger mice, low bone formation is considered to be the cause of bone loss, whereas in older mice increased osteoclastogenesis has been thought to contribute significantly to bone loss. 198 Some of the adverse effects of rosiglitazone have been prevented in rats with cotreatment with metformin.
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Studies in rodents exposed to pioglitazone have found either no adverse effects on bone 142,205 or negative effects. Several studies found that pioglitazone resulted in decreases in BMD, 199, 202, 206 decreased bone strength, 199, 207 decreased osteoblast surface and mineralizing surface, and increased osteoclast surface and number, 199 supporting that pioglitazone suppresses bone formation and promotes bone resorption, 207 predisposing to bone fragility. These effects have been reversible in certain studies 206, 207 with discontinuation of treatment. Interestingly, when pioglitazone treatment has been combined with fenofibrate (a PPARα agonist) administration, the negative effects on bone were either unaffected 207 or attenuated. 206 Lastly, lobeglitazone did not have any negative effect on whole body and femoral BMD in mice compared with vehicle. no difference 208, 209 or a decrease in osteocalcin, 211 and an increase in sclerostin 166 levels. Likewise, a meta-analysis including 14 trials found considerable variation in bone turnover markers between studies. 179 TZDs have also been shown to have no effect 209 214 One study reported that TZD use (troglitazone, pioglitazone, and/or rosiglitazone) was associated with significant bone loss in older women with T2D at multiple sites 215 and another study showed lower BMD of spine and total hip compared with metformin involving both men and women with T2D. 158 However, when compared with insulin or exenatide treatment specifically, Li et al found no difference in BMD or bone turnover markers with pioglitazone. 216 Grey et al found that pioglitazone when compared with control was associated with increased bone loss at the femur but no other sites. 217 Finally, a recent meta-analysis on the effects of TZDs on bone reported decreases in BMD at the lumbar spine, total hip, and forearm. 179 Admittedly, however, effects of TZDs on BMD do not predict effects on the risk for fracture from TZD exposure.
Interestingly, the newer TZD, lobeglitazone, when compared with placebo over a 52-week treatment period, was not associated with a significant decrease in BMD 218 in 112 adults with T2D (mean agẽ 56 years; duration of T2D~4 years); however, these relatively better skeletal outcomes need to be confirmed with further studies, as there are no long-term data yet available. compared with men (M + SU = 5.2% vs R = 7.2%). 219 These findings have been confirmed in a meta-analysis involving patients with T2D treated with pioglitazone or rosiglitazone. All studies showed an overall increased risk of fractures with TZDs, and half of them showed an increased risk in women with T2D (double risk of fracture), but not in men. 220 A more recent meta-analysis of 22 randomized clinical trials using pioglitazone or rosiglitazone treatment for T2D patients (24 544 subjects) concluded that TZDs are associated with increased risk of fractures in women and that the fracture risk does not depend on age or duration of exposure to TZD. 41 Other studies have also reported on increased risk, particularly in women treated with a TZD. [220] [221] [222] [223] Additionally, another study found that the fracture incidence in patients with T2D treated with a TZD was 39% higher compared with control patients, and that the risk was increased irrespective of gender after the age of 50 years. 224 This risk was reported to be almost identical between rosiglitazone and pioglitazone. 224 An increased prevalence of vertebral fractures was reported in male patients with T2D treated with TZD and metformin compared with metformin alone, supporting that men are also at risk of fractures when on TZDs. 225 Other investigation supported the conclusion that fracture risk is independent of age and sex, with similar risk in both sexes (OR = 2.5 for men, OR = 2.56 for women). 154 Few studies have found no increased risk of fractures with pioglitazone. 226 Based on the ACCORD Bone study, follow-up of female patients who had discontinued TZDs showed that fracture risk is reduced within 1 to 2 years of discontinuation. 227 The increased fracture risk observed in patients with T2D treated with TZDs is likely multifactorial, and both the deleterious effects of diabetes on bone in combination with the exposure to a TZD contribute towards this increased risk.
Although several studies have shown the negative effects of TZDs on bone even in healthy populations without diabetes 228 and in those with prediabetes, 229 a study designed to treat women with impaired fasting glucose or impaired glucose tolerance testing with pioglitazone for 12 months showed that women treated with TZDs were found to have similar BMD and bone markers as the control group. 230 This finding supports that pioglitazone alone might not be sufficient to cause bone loss, although BMD change, by itself, may not be an adequate marker for fracture risk in this population.
Conclusion
Review of the published clinical trials that have assessed TZDs and risk of fracture supports the concern that this class of medications, and especially rosiglitazone, is associated with a significantly higher risk of bone fracture compared with other available hypoglycemic agents. are oral hypoglycemic agents which bind to the regulatory SUR1 subunit of the β-cell KATP channel, resulting in channel closure, membrane depolarization and insulin release. 233 Tolbutamide and gliclazide (a first and a second generation SU, respectively) block, specifically, KATP channels containing SUR1 subunits (present in the β-cell membrane) whereas glibenclamide and glimepiride (a second and a third generation SU respectively), along with repaglinide (GLD) block KATP channels containing both SUR1 and SUR2 subunits (cardiac, skeletal, and smooth muscle) with different potencies. 233, 234 The different affinities of SUs for different tissues at therapeutic doses relate to the differences in the adverse effects of these drugs in a specific tissue, eg, the cardiovascular risk. Furthermore, variations in the composition of both SUR and Kir6.x subunits explain the differences between the electrophysiological and pharmacological properties of the KATP channels in different tissues. suggesting that SUs may have direct effects on bone cell physiology.
Skeletal effects: In vitro
KATP channels appear to have different sensitivities to channel blockers such as SUs: they can be responsive to glipizide or glibenclamide, as was described in the MG-63 osteoblast cell line, 238 or insensitive to glibenclamide (but sensitive to ATP) as shown in human primary periodontal ligament cells. 237 This might be due to different SUR subunits assembling to various Kir6.x subunits in a tissuespecific manner, resulting in different types of KATP channels. In primary osteoblasts, inhibition of KATP channels with glibenclamide showed no effect on osteogenic gene expression. 238 Hyperglycemia has been shown to suppress the PI3K/Akt/eNOS pathway in rat osteoblasts and therefore interfere with osteoblast transcription factors, such as RUNX2, critical for their differentiation and proliferation. [239] [240] [241] In addition, hyperglycemia-induced reactive oxygen species formation contributes to adipogenesis and inhibition of PI3K/Akt-mediated osteogenic differentiation. 242 In rat osteoblasts, glimepiride activates the PI3K/Akt pathway 239, 240, 243 inducing the proliferation and differentiation of these cells in vitro. In other studies, glimepiride (10 μM) induced the tyrosine phosphorylation of IRS1/2, accumulation of activated PI3K and Akt phosphorylated at Ser 473, and enhanced both total eNOS and eNOS phorphorylated at Ser 1177, a downstream regulator of the PI3K/Akt pathway and a cell survival signal. 243 The eNOS activation by glimepiride (but not glibenclamide) was also described in human endothelial cells, 244 and a role for eNOS in the regulation of bone development and metabolism has also been suggested by Saura et al. 245 In the context of diabetic bone disease, glimepiride reverses the inhibitory effect of high glucose on the PI3K/Akt/eNOS pathway, enhancing the expression of RUNX2, osteocalcin, and alkaline phosphatase mRNA and significantly increasing the differentiation capability of osteoblasts.
Glimepiride was also reported to enhance bone formation by osteoblasts in a high glucose (16.5 mM) microenvironment. 239, 240 Recently, it was reported that the activation of the NLRP3 inflammasome in human mesenchymal stem cells, a major pathway involved in β-cell failure and multiple complications of T2D, also impairs osteogenic differentiation and promotes adipocyte differentiation. 246 Therefore, new SU molecules have been designed to target both the KATP channels and NLRP3 activation, 247 opening the way for a new generation of SUs that could act on both the pancreatic β-cell and on bone.
Skeletal effects: In vivo
In vitro data indicate a potential beneficial role for SUs in bone metabolism; however, only limited data exist on the impact of this class of drugs on bone health in animal models. Experiments in ovariectomized rats have demonstrated that glimepiride (given once daily, for 28 days)
inhibited the changes in BMD and bone remodeling caused by estrogen deficiency; this beneficial effect was also observed in nonovariectomized rats, albeit to a lesser extent. 248 Therefore, it was suggested that glimepiride may reduce the development of osteoporosis in post-menopausal women.
Skeletal effects: Clinical investigation and fracture risk
The SUs have been widely prescribed since 1950 and three genera- or 104 weeks of treatment with either of these medications. 252 The risk of fracture from SUs has, to date, predominately been associated with the risk of falls due to hypoglycemia [253] [254] [255] [256] with SU therapy, and not to a direct effect of the drugs on bone remodeling (bone turnover markers) or integrity (ie, BMD). 252, 257 Because SUs increase both first and second phase insulin release by β-cells (in a glycaemia-independent manner), hypoglycemia is a known risk factor of the SUs. This side-effect, although rarely occurring as "symptomatic," 258 is more likely to appear at the beginning of treatment, mainly with the long-acting SUs (glyburide, glibenclamide) rather than with the short-acting medications (gliclazide, glipizide, tolbutamide), at higher doses, after exercise or a missed meal, and in patients with a higher risk for hypoglycemia. 
| Meglitinides (Glinides)

Mechanism of action
Glinides, including repaglinide and nateglinide, are a class of oral, mealbased medications intended for the control of post-prandial hyperglycemia. They stimulate insulin exocytosis by closure of the KATP channels of pancreatic β-cells, a mechanism of action they share with the SUs. Nateglinide binds the A-site on SUR1 subunit while repaglinide binds the B-site on both SUR1 and SUR2 subunits. 234 In addition, glinides trigger intracellular Ca2+ release from the endoplasmic reticulum via ryanodine receptor activation, contributing to the enhancement of insulin secretion independently of KATP channel activity. 266 However, long-term exposure to glinides (as well as to SUs) accelerates KATP channel dysfunction and pancreatic β-cell apoptosis and failure ("secondary failure") over time. 267 The glinides are rapid-onset and short-acting (T1/2~1 hour) insulinotropic drugs. They are prescribed in patients with significant post-prandial hyperglycemia (and are administered prior to meals), acting faster and with shorter duration than SUs and displaying less propensity to elicit hypoglycemia (nateglinide < repaglinide) than SUs, 268 except in patients with advanced chronic kidney disease, and in association with insulin 269 or in combination with TZDs. 270 
Skeletal effects: In vitro
We have not identified any published information on the in vitro skeletal effects of the meglitinide class of anti-diabetic medications.
Skeletal effects: In vivo
The effects of repaglinide on fertility, on embryo-and fetogenesis and on peri-and postnatal development in rats were studied by Viertel et al. 271 This study revealed skeletal changes in the extremities of the offspring when dams were exposed to repaglinide (30 and 80 mg/kg) during late pregnancy and/or lactation; these alterations included deformities of the scapula, of the proximal humeral epiphysis, and of the femur. 271 However, these skeletal alterations appeared at very high plasma concentrations, outside of the concentration range reached with the human therapeutic dose. GLP-1 has been shown to affect bone metabolism, specifically by promoting osteoblast proliferation and inhibiting osteoblast apoptosis in murine osteoblasts. 278 GLP-1 has also been found to have indirect effects on inhibiting bone resorption by upregulation of calcitonin (CT) in mice. 279 GIP has been shown to promote bone formation, partly through its direct action on osteoblasts where it improves collagen maturity 280 but also by inhibiting osteoblast apoptosis and by affecting calcium deposition in bone. 281 Furthermore, GIP has been shown to inhibit the activity of mature osteoclasts. 282 Moreover, a safety announcement by the US FDA was published regarding arthralgia reported with the use of DPP-4 inhibitors, introducing a potential musculoskeletal complication of mobility-limiting joint pain with these medications.
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Skeletal effects: In vitro A DPP-4 inhibitor, MK-0626, was shown to have no effect on osteoblast differentiation. 286 Saxagliptin has been shown to inhibit
Runx2 and Ocn expression, as well as type-1 collagen production and mineralization, in bone marrow stromal cells from rats and in the MC3T3E1 cell-line. 287 Sitagliptin reduced osteoclast-specific markers in murine macrophages and suppressed RANKL-mediated osteoclastogenesis. healing by reducing adipocyte accumulation in the bone marrow. 291 An attenuation of bone loss in diabetic rats along with lower CTX levels was also shown with sitagliptin treatment. 290 Interestingly, pharmacologic reduction in DPP-4 showed an improvement in the bone phenotype of mice, whereas genetically induced reduction of DPP-4 (DPP-4 knockout mice) was not associated with such changes. 289 Vildagliptin was also found to have beneficial effects on BMD and bone microacrchitecture 292 and has even been shown to restore bone changes induced by pioglitazone treatment in a T2D animal model. 293 Another DPP-4 inhibitor, MK-0626, had neutral effects on bone in a T2D mouse model. 286 Saxaglitpin, on the other hand, when administered to rats had a negative effect on osteoblast number and metaphyseal trabecular bone osteocytic density. Sitagliptin has not been associated with an increased risk of fracture based on published studies 265, 298 and a meta-analysis that included 27 trials evaluating sitagliptin use 299 ; however, a recent cohort study with 1578 participants concluded that sitagliptin use for longer than 250 days was associated with increased risk for fracture (aHR: 1.32). 300 The reason for these conflicting findings regarding sitagliptin therapy is unclear, but differences in compliance and duration of therapy, age, and glycemic control of subjects between these studies could account for some of the discrepancies. 278, 317 and most studies support that they promote proliferation and differentiation of these cells. 317, 318 Liraglutide has also been shown to inhibit apoptosis of murine osteoblasts. 319 A reduction in sclerostin in murine osteocytes and in diabetic rats treated with exendin-4 312 suggests that an interaction between this class of medications and the Wnt signaling pathway might be responsible for the bone promoting effects of GLP-1R agonists, a finding that has been suggested by other investigators. 320 However, it is unclear whether the mechanism of action of GLP-1R
| GLP-1R agonists
agonists in murine bone is direct, or indirect, involving inhibition of bone resorption by CT. 279 The effects of GLP-1 on CT secretion appear to be prominent in rodents as the concentration of the GLP-1R is higher in thyroid C cells from rodents compared with thyroid C cells from humans. In fact, human C cells have been shown to be less responsive to GLP-1-mediated CT release. 
Skeletal effects: Clinical investigation and fracture risk
There is no evidence currently to suggest that GLP-1R agonists are associated with increased fracture risk. 183, 185, 294 Instead, similar to DPP-4 inhibitors, these agents are viewed as having beneficial or neutral effects on the skeleton of patients with diabetes.
Some data on bone biomarkers and/or BMD is available, although these findings would not directly predict fracture risk. Specifically, a recent, two-center, randomized, parallel-group clinical trial compared the effects of exenatide on BMD and bone turnover markers to insulin or pioglitazone treatment (n = 62 newly diagnosed T2D patients) and did not find any improvement in either BMD or bone biomarkers after 24 weeks of treatment despite improvements in glycemic control. 216 Similarly, exenatide did not affect BMD despite significant weight loss in a group of T2D patients, nor did it change alkaline phosphatase levels. 327 Another study looking at the effects of liraglutide monotherapy (1.8 or 1.2 mg/day) compared with glimepiride (8 mg/day) on BMD of patients with T2D did not detect any differences in BMD change from baseline across treatment groups over 2 years of treatment. 252 In comparison, liraglutide was shown to increase the bone formation marker P1NP, but in a group of weight-reduced obese, otherwise healthy (non-diabetic) women, while not affecting the bone resorption marker CTX-1.
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With respect to fracture risk, an early meta-analysis did not report an increased or decreased risk of fractures with GLP-1R agonists. 329 This was followed by a meta-analysis involving 14 randomized control trials that also did not provide any evidence of an effect on fracture risk. 330 Liraglutide has been associated with decreased fracture risk 330 whereas exenatide with increased risk. 330 335 Differential effects with the use of short-acting versus longacting GLP-1R agonists on the musculoskeletal system could also be responsible for lack of consensus between studies. 
Conclusion
| Glucosurics
| SGLT2 inhibitors
Mechanism of action
Selective sodium-dependent glucose co-transporter 2 inhibitors (SGLT2Is) are one of the newest anti-hyperglycemic drug agents, with canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin currently FDA approved in the United States. They exert glucose lowering effects by inhibiting renal glucose reabsorption and promoting glucosuria. Specifically, this class of drugs ("gliflozins") inhibits the renal co-transport (ie, reuptake) of glucose and sodium (Na + ) within the early proximal convoluted tubule, by blocking the SGLT2 cotransporter. [336] [337] [338] [339] [340] In this way, enhanced glucose excretion leads to blood glucose lowering, through an insulin-independent mechanism.
SGLT2Is are effective as monotherapy, 341, 342 or as co-therapy, in combination with insulin, 343, 344 or with a variety of oral hypoglycemic agents [345] [346] [347] [348] in the treatment of T2D. Recent studies also suggest that SGLT2Is may be efficacious, as adjunct-to-insulin therapy, in the treatment of T1D. 349, 350 In persons with T2D treated with SGLT2Is, net caloric loss attributable to glucosuria also contributes to a modest but beneficial weight loss. 337, 339, 340 Additionally, cardiovascular risk reduction, including a reduction in cardiovascular death and heart failure-related hospitalizations, has been documented in patients treated with empagliflozin and canagliflozin, increasing the appeal and utilization of this drug class in at-risk individuals. 351, 352 Overall, these medications are considered highly efficacious in lowering glucose, particularly in T2D patients with normal renal function. 12 In conjunction with blockade of renal glucose reuptake, blockade of Na+ reuptake from the tubular lumen also results, which can alternatively be reabsorbed via the sodium/phosphate co-transporter; theoretically, the resulting secondary increase in serum phosphate concentration could induce a compensatory physiological increase in both parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), to induce phosphaturia and maintain normal serum phosphorus concentration. Chronic glucosuria augmented by SGLT2I therapy could also contribute to diabetic hypercalciuria via osmotic diuresis. [353] [354] [355] In total, blood glucose would decrease, but potentially 
SGLT2 expression was not detected in cells of either the osteoblast
or osteoclast lineages; SGLT1 was detected in MC3T3-E1 differentiating osteoblasts, albeit at levels <1% of that observed in the kidney, but not in any cells of osteoclast lineage. 357 Studies using radio-fluorinated labeling of dapagliflozin have also examined organ specific SGLT2-inhibitor binding in rat tissues, and while skeletal binding was not assessed, no specific binding to skeletal muscle was observed. 358 Similarly, mRNA expression of SGLT1 in muscle tissue of control and diabetic rats was found to be negligible. 359 Taken together, these studies indicate that SGLT2-inhibitor drugs are unlikely to have a specific direct effect on musculoskeletal tissues at the cellular level.
When examined systemically, either pharmacologic or genetic inhibition of SGLT2 function appears to result in some disruption of bone mineral homeostasis in animal models. Theoretical mathematical modeling of Ca+ reabsorption in the renal proximal tubule predicts that SGLT2 blockade in the PT should contribute to hypercalciuria. 360 Consistent with this concept, canagliflozin-treated diabetic mice (~10-20 mg/kg/day dose) exhibit persistently increased urine calcium excretion, along with increased serum FGF23 concentration, and biomarker evidence of bone resorption, despite a significant improvement in glycemic control compared with their untreated diabetic counterparts. 357, 361 Increased urinary calcium excretion has also been reported in rats exposed to a supra-physiological dose of canagliflozin (100 mg/kg/day), 362, 363 but this was jointly attributed to off-target effects, via SGLT1, to increase intestinal calcium absorption. 362 The Sweet Pee mouse, however, which carries a nonsense mutation in the Slc5a2 gene resulting in genetic loss of SGLT2 protein function, also exhibits urinary calcium and magnesium wasting, along with growth retardation. 364 In rats, again in toxicology studies, increases in serum phosphorus were also reported following supra-physiological exposure to empagliflozin. 365 Systemic effects of the SGLT2Is on bone mineral content have also been reported in animal models. Supra-physiological exposure to dapagliflozin at > 2000-fold MRHD resulted in trabecular bone accretion, and tissue mineralization, but again attributed to off-target effects to increase intestinal calcium absorption. 366 In contrast, a 9-week study of the effects of ipragliflozin in the GK rat model of non-obese T2D
found no change in bone mineral content compared with control mice although body fat mass was lowered by SGLT2I treatment. 377 An increase in both osteocalcin, a marker of bone formation, and in CTX, a marker of bone resorption, suggested an increase in bone turnover, but attributed in part to treatment-related weight loss. 377 Similarly, in a short duration, Phase 2b, 12-week, double-blind, study of canagliflozin (50 mg vs 100 mg vs 300 mg; once daily) given to overweight or obese subjects without diabetes (n = 376 randomized), study participants achieved a 2.2% to 2.9% body weight reduction, again accompanied by a significant increase in CTX in the canagliflozin treatment groups.
However, no change in bone formation markers (bone-specific alkaline phosphatase, osteocalcin, P1NP) or in urine N-telopeptides was observed. 378 In contrast, in adults with T2D inadequately controlled on metformin, dapagliflozin treatment (10 mg, once daily; NCT 00855166), whether analyzed at~1 379 or 2 years 337 of treatment, had no impact on bone biomarkers or on BMD. Also, in patients with T2D, after 2 years of treatment empagliflozin exposure did not cause a significant change in alkaline phosphatase or urinary N-telopeptide compared with placebo, 374, 380 and at 26 weeks of treatment ertugliflozin had no adverse effect on BMD. 381 
Effects on fracture
Early clinical investigation in T2D demonstrated a possible~30% increase in bone fractures in patients receiving canagliflozin for a duration of 68 weeks 376 ; moreover, bone fractures were seen as early as 12 weeks after starting canagliflozin. Additionally, in patients with moderate renal impairment receiving dapagliflozin for 104 weeks, 7.7% of subjects experienced a bone fracture, compared with no fractures in the placebo group. 382 In contrast, by cumulative metaanalyses of randomized controlled trials, along with systematic literature review, several later publications have subsequently demonstrated that the incidence of skeletal fracture, compared with placebo, does not appear to be increased across the currently available SGLT2 inhibitor drugs when used for the treatment of T2D. [383] [384] [385] However, it is also recognized that the duration of treatment, and duration of patient follow-up for most of these studies remains relatively short for evaluating any treatment-emergent effect on skeletal integrity and strength. Additionally, possible differences between individual medications within this drug class have been identified. Therefore, a discussion of available drug-specific findings is also included. Additionally, a greater incidence of hyperphosphatemia and PTH elevation was present in these patients with renal impairment; and, higher rates of peripheral neuropathy and orthostatic hypotension also existed, possibly contributing to fall risk. 382 Together, these findings indicated that while fracture risk was increased, findings were again likely to be specific to the at-risk patient population studied in that trial.
In comparison, a randomized, double-blind, placebo-controlled trial of dapagliflozin (10 mg) treatment added to metformin in 140 adults with T2D (NCT00855166) found no change in fracture incidence or in BMD by dual X-ray absorptiometry, after 102 weeks of treatment. 337, 379 Similarly, a study of dapagliflozin (5 mg vs 10 mg)
given as add-on to insulin in Japanese patients with T2D (DAISY)
reported no increased incidence of fracture after 52 weeks of treatment; additionally dapagliflozin was insulin-sparing. 389 A populationbased, open cohort study, using The Health Improvement Network, comparing 4548 T2D patients on dapagliflozin with 18 070 patients matched for age, sex, BMI, and diabetes duration, all on other standard-of-care diabetes drugs, also detected no increase in the primary outcome of fragility fracture, and no increase in any treatmentemergent fracture, even among patient at high risk for fracture. Empagliflozin: Pooled data from 15 phase 1-3 RCTs along with four extension trials, comparing Empagliflozin (10 or 25 mg) with placebo for the treatment of T2D, encompassing >4000 subjects per treatment group and >15 000 combined patient-years of drug exposure, found no difference in the rates of fracture across treatment groups.
374,380
Ertugliflozin: As yet, there are no published reports specifically comparing fracture risk among patients with T2D exposed to ertugliflozin. The VERTIS MONO clinical trial (NCT01958671) evaluating ertugliflozin monotherapy over 52 weeks (5 mg vs 15 mg vs placebo) in adults with T2D inadequately controlled on diet/exercise alone reported the occurrence of two adjudicated, non-serious hand fractures, both in the ertugliflozin 15-mg dose group, although the overall incidence of drug-related adverse events was otherwise similar across the treatment groups. 371 However, the VERTIS SITA2 study could not identify reports of skeletal toxicity or skeletal malformation in these preclinical studies. 401 A more recent study utilizing the GK rat model of T2D found that treatment with voglibose, one of the newest α-GI drugs (approved for use in Asia), was insufficient to reverse the negative effects of diabetes on osteo-integration of dental implants. 402 From this study, the authors inferred a detrimental effect of α-GI treatment on bone repair, although incomplete glycemic control could also account for their findings. 402 Considering the longevity of this drug class, it is reasonable to assume that post-marketing surveillance would identify a serious musculoskeletal safety concern, although teasing out a class-specific contribution from these drugs could be difficult, considering that they are used less often and typically only in select multi-component therapy.
Conclusion
At present, there is little information available as to either the musculoskeletal benefit or harm from alpha glucosidase inhibitors. At the same time, amylin inhibits osteoclastic bone resorption and/or lowers plasma calcium as demonstrated in mice, rats, and rabbits. 417, 418 In rats specifically, an amylin-induced decrease in osteoclast surface (OcS/BS) and erosion surface (ES/BS) has been illustrated by dynamic histomorphometry. 415 In humans, similar to CT, amylin also exhibits both hypocalcemic and osteoclast inhibitory properties, 419, 420 although at a much reduced potency. As would be consistent with these anti-resorption effects, mice with targeted deletion of the amylin gene exhibit low bone mass, attributable to chronically unrestricted bone resorption. 421, 422 Additionally, daily amylin treatment has been shown to inhibit ovariectomy-induced trabecular bone loss in rats, again by inhibiting bone resorption. 423 In preclinical investigation, somewhat conflicting results have been reported from studies examining the effects of amylin replacement on diabetic bone loss specifically. In streptozotocin (STZ)-induced diabetic Wistar rats (a model of T1D), 40 daily injections of amylin (1000 pmol/kg/day) resulted in improved bone strength and bone density to levels indistinguishable from nondiabetic control rats. 424 Similarly, in a Wistar rat model of T2D, amylin treatment for only 3 days via continuous infusion (720 pmol/kg/day) resulted in an increase in osteoblast number and osteocalcin mRNA expression in long bones. 415 However, in a study of STZ-induced diabetic Sprague-Dawley rats, 19 daily injections of amylin (45 μg/ kg/day) did not rectify the low-turnover osteopenia which was characteristic of diabetic animals, 425 but perhaps due to the supra-physiological, 1000-fold difference in treatment dose used in this study.
Altogether, the combination of generally pro-osteogenic and antiresorptive effects of amylin infers that pramlintide might be similarly advantageous in diabetic bone disease. However, only one study has directly examined the skeletal effects of pramlintide therapy in humans. In a study of 23 non-osteoporotic T1D patients (mean agẽ 45 years; mean duration of T1D~21 years), 12 months of treatment with pramlintide, as four injections per day, did not impart a significant change in BMD, or in bone biomarkers (calcium, PTH, osteocalcin, pyridinium cross-links) after 1 year. 426 However, because these subjects were not osteoporotic at baseline, the implication of these findings may be limited; moreover, they do not provide any evidence of the impact of pramlintide on fracture risk, specifically.
At present, there is little information available as to either the musculoskeletal benefit or harm from amylin mimetics.
3 | DRUGS AND MUSCLE
| Overview
Diabetes mellitus is associated with muscle loss and atrophy, particularly in older individuals where age-related sarcopenia is also often observed. 274, [427] [428] [429] [430] [431] Rodent models of T1D and some rodent models of T2D (db/db mice) are characterized by muscle atrophy and impaired muscle function. 432 Muscle atrophy, weakness, and functional impairment have also been documented in humans with T1D 429,433-437 and T2D. 430, 431, 433 Decreased physical activity or disability, aging, obesity, hyperglycemia, oxidative stress, mitochondrial dysfunction, inflammation, reduced insulin/IGF-1 signaling, and diabetic neuropathy are only some of the proposed mechanisms that contribute to diabetesassociated muscle wasting. 274, 429, 433, 438 Skeletal muscle is considered the major site for insulin-mediated glucose disposal and energy metabolism. Therefore, its role in glucose homeostasis is crucial. Muscle wasting can exacerbate insulin resistance, which in turn can lead to further muscle loss. 439 In addition to insulin, several antihyperglycemic medications act on skeletal muscle and, therefore, could affect diabetes-induced muscle loss. [441] [442] [443] and improves mitochondrial capacity in skeletal muscle. 444 Insulin resistance or insulin deficiency is associated with muscle wasting, partly due to increased protein degradation. 445, 446 In an animal model of T1D (90% partial pancreatectomy)
impaired muscle growth and function was observed, secondary to impaired protein synthesis in Type II (fast twitch) fibers. 447 Insulin withdrawal in insulin-deficient rats resulted in a decrease in protein synthesis and increase in protein degradation, 448 while STZ-induced insulinopenia in mice resulted in an increase in protein degradation and decreased muscle mass, 449 supporting the critical role of insulin in protein homeostasis.
Although in humans with T1D, inhibition of protein breakdown is observed with insulin treatment, 446 protein synthesis is not consistently achieved with insulin administration, 450, 451 and a relative resistance to the action of insulin has been observed 452,453 affecting glucose, protein metabolism, and mitochondrial function. In a study evaluating body composition in persons with T1D, only a small increase in lean body mass was observed during the first year of insulin therapy. 454 However, another study comparing changes in body composition of newly diagnosed diabetic patients on insulin therapy revealed a significant increase in lean mass in patients with T1D within 6 months of treatment. 455 Furthermore, patients with T1D assigned to intensive insulin therapy were noted to have greater weight gain and muscle mass compared with those on conventional therapy. 456 These studies support that insulin is imperative for skeletal muscle mass and metabolism; some of the benefits on skeletal muscle associated with insulin therapy are likely indirect, due to insulin's effect on glycemic control.
In humans with T2D, greater muscle mass due to larger body size may exist, compared with healthy adults; however, their muscle performance is negatively affected. 457 Also, with age, muscle wasting in patients with T2D is evident. 431 In certain animal models of T2D, such as the db/db mice, decreased exercise capacity and muscle weight have been observed; however, other models of T2D, such as the TallyHo mice, do not exhibit muscle atrophy and loss of muscle function. 458 This indicates that additional factors to hyperglycemia and insulin resistance are necessary for muscle loss in T2D. In a rat model of T2D, insulin therapy was shown to improve lean mass 459 ; however, in humans with T2D, insulin therapy is considered to be ineffective for improving muscle mitochondrial function, 460 increasing protein synthesis, 461 reversing skeletal muscle proteolysis, 462 or improving muscle strength. 463 Furthermore, insulin therapy in patients with newly diagnosed T2D was not associated with skeletal muscle gain 455, 464 contrary to patients with T1D. 455 A study looking at skeletal muscle index (the ratio of appendicular muscle mass to total body weight, expressed as a percentage value) in T2D subjects treated with: oral hypoglycemic agents alone; insulin alone; or a combination of both;
found higher skeletal muscle index in older patients (≥65 years) receiving insulin. Interestingly, the same study reported that endogenous insulin secretion, measured by stimulated C-peptide immunoreactivity, was negatively correlated with skeletal muscle index in T2D patients. 465 Future studies are needed to identify the risk factors associated with insulin resistance that predispose to muscle atrophy and dysfunction. The contribution of insulin therapy towards improvement in muscle mass and function is more evident in patients with T1D, whereas in patients with T2D, insulin therapy's benefits on skeletal muscle are not as promising due to insulin resistance.
Biguanides
Metformin activates AMPK, resulting in inhibition of protein and lipid synthesis and increased fatty acid oxidation and glucose uptake. 466 Recent data suggests that skeletal muscle repair may be improved when AMPK is activated. 467 Metformin has been proven beneficial for protein metabolism in a cachexia model of tumorbearing rats. 468 Metformin has also been shown to improve mitochondrial function in skeletal muscle 466 and induce irisin release, an exercise-induced myokine, with beneficial effects in adipose tissue metabolism in mice. 469 A few clinical studies have shown effects of metformin in muscle morphology and muscle function. Muscle mass loss was significantly reduced in older diabetic men on insulin sensitizer therapy, with either metformin or TZD, 470 while in another group of newly diagnosed patients with T2D, the skeletal muscle index was improved in men, but not in women, after 24 weeks of metformin treatment. 471 Results from another study showed that the lipid content of vastus lateralis muscle in T2D patients was decreased with metformin therapy, although this decrease was not associated with improvement in the glucose-disposal rate. 472 Another recent study from Indonesia reported improvement in gait speed but not grip strength in elderly patients treated with 1500 mg/day of metformin. 473 Although most of the studies have proposed that metformin is beneficial for muscle function, recent studies that have evaluated the effects of metformin on aerobic capacity have found a reduction in aerobic capacity with metformin treatment, 474, 475 suggesting that metformin might be attenuating exercise-induced benefits on insulin sensitivity and cardio-metabolic health. 476 Another study, however, noted that there was no metformin-mediated attenuation of exercise benefits on glycemic control. 477 Potential side effects of metformin involving the musculoskeletal system include myalgia and muscle weakness. Ongoing studies are evaluating the effects of metformin on muscle mass and physical performance in insulin resistant and older individuals (NCT01804049, NCT02308228).
Thiazolidinediones
Activation of PPARγ in muscle has proven to be protective against insulin resistance. 478 TZDs in mice have shown promising results against muscle wasting. Rosiglitazone has been shown to reduce proteolysis and muscle atrophy in db/db mice by decreasing caspase-3
and proteasome activity 445 and decreasing cachexia markers, Atrogin-1 and Muscle RING-finger protein-1 (MuRF-1), in the skeletal muscle of mice with cancer cachexia. 479 Pioglitazone was shown to suppress oxidative stress and inflammation in skeletal muscle of mice with spinal and bulbar muscular atrophy. 480 In patients with T2D, pioglitazone and troglitazone were found to improve myocellular lipid metabolism, 472, 481, 482 without any changes in mitochondrial function in skeletal muscle. 472, 481 In contrast, another study of subjects with T2D showed increased or decreased mitochondrial respiration of skeletal muscle with pioglitazone or rosiglitazone, respectively. 483 Additionally, pioglitazone treatment was shown to improve markers of inflammation in skeletal muscle of patients with PCOS. 484 However, pioglitazone did not prevent skeletal muscle loss when compared with resistance training in a group of older, nondiabetic overweight, or obese subjects enrolled in a hypocaloric weight-loss program. 485 Evaluation of the transcriptome of skeletal muscle of subjects with impaired glucose tolerance on pioglitazone therapy did not reveal any metabolic pathways that were modulated by pioglitazone. 486 TZDs appear to be relatively safe, and although acute rhabdomyolysis after pioglitazone use has been reported, 487 other skeletal muscle-related adverse events appear to be uncommon with TZD use. 488 The majority of the studies support a positive or neutral effect of TZDs on skeletal muscle, however additional studies are required to confirm these effects, particularly in the diabetic population.
Sulfonylureas and meglitinides
Sulfonylureas act on the plasma membrane KATP channel of different tissues causing changes in potassium intracellular flow. They have direct effects on muscle, affecting glucose uptake, glycogen synthase activity, 489 protein degradation, 490 and mitochondrial function in skeletal muscle. 491, 492 Gliclazide can improve skeletal muscle glucose uptake, and this effect appears to be mediated by action on the KATP channel 493 and associated with an increase in GLUT-1 membrane content and either no change 494, 495 or an increase 496 in the GLUT-4 expression and content in skeletal muscle. Recent studies suggest that SUs and glinides can induce muscle atrophy; reduced muscle protein content/muscle weight as well as reduced muscle fiber diameter was shown with SU and glinide treatment in mice. 497 Glibenclamide/glyburide, but not other SUs, has been associated with muscle atrophy in humans, based on reports in the FDA-Adverse Effects Reporting System (AERS) database over an observation period of 8 months. 497 The underlying suggested mechanisms for muscle atrophy appear to be hypoglycemia and/or KATP channel blocking. 497 Interestingly, glibenclamide has been shown to increase tension in fatigued slow muscle in mice 498 and in chickens 499 supporting a direct effect of SUs on the KATP channels of skeletal muscle.
Sulfonylurea and glinide use is rarely associated with skeletal muscle-related adverse events.
Incretins
Animal studies of GLP-1R agonists have shown beneficial effects on skeletal muscle, partly due to their insulin-like effects on glucose utilization in skeletal muscle. 500 GLP-1 has been shown to increase glucose uptake in skeletal muscle, 501, 502 an effect that is mediated by nitric oxide. 501 Exendin-4 has been shown to enhance glucose transport in skeletal muscle of diabetic rats 502 and both exenatide and liraglutide promote glucose uptake in skeletal muscle through AMPK activation. 503 Exendin-4 increases glycogen synthase activity and glucose incorporation into glycogen and stimulates glucose utilization and oxidation in muscle. 504 Other effects are suggestive of glucoseindependent effects of GLP-1R agonists on muscle. 508 Exenatide has also been shown to increase irisin, a myokine that is commonly induced by exercise, in patients with T2D. 509 Furthermore, in a clinical study, liraglutide was associated with an increase in the skeletal muscle index in overweight and obese patients with T2D. 510 Despite these positive reported actions of GLP-1R agonists on skeletal muscle, a very recent study from Japan evaluating changes in body composition of patients with T2D on hemodialysis showed decreases in skeletal muscle mass with 6 months of dulaglutide therapy, compared with teneligliptin therapy, raising some concern about dulaglutide-induced muscle loss. arthralgia. 284, 285, 515 Proposed mechanisms for these adverse events include a change in pain threshold or DPP4 inhibition in skeletal muscle. 284 Additionally, case reports have been published describing that sitagliptin, when combined with a statin, is associated with rhabdomyolysis. [516] [517] [518] Further studies are required to elucidate the underlying mechanisms and risk factors for these adverse events. Interestingly, acute toxicity associated with skeletal muscle necrosis has been reported with vildagliptin administration in monkeys, although the authors of this study reported that this is a monkey-specific phenomenon, with no relevance to humans.
519
SGLT2 inhibitors
Little is known about the effects of SGLT2Is on skeletal muscle.
SGLT2Is have been shown to increase skeletal muscle glucose uptake 520 and reduce insulin resistance at the skeletal muscle. 
Glucosidase inhibitors
Acarbose's effects on skeletal muscle have been studied in genetically obese Zucker rats, a model of insulin resistance. Acarbose was found to induce GLUT-4 trafficking by inducing Akt activation in skeletal muscle. 527 In a clinical study evaluating lipid deposition in skeletal muscle in individuals with metabolic syndrome, no changes in lipid metabolism in the muscle were observed with miglitol therapy. 528 No adverse events of glucosidase inhibitors on skeletal muscle have been reported.
Amylin mimetics
Amylin has been reported to decrease glycogen storage in skeletal muscle of rodents. A study evaluating the effects of the human amylin analog AC137 showed increased lactate release from skeletal muscle under hypoglycemic conditions in T1D patients. 529 No other reports of amylin mimetic effects on skeletal muscle were found.
Conclusions
Skeletal muscle is negatively affected in diabetes due to multiple factors, and evaluating these factors in an environment of insulin resistance and/or deficiency is critical. There is an unmet need for studies assessing muscle morphology and function in diabetes, and for clinical trials focused on the anti-diabetic therapies and their role in preventing diabetes-associated muscle impairment.
| FUTURE DIRECTIONS AND CONSIDERATIONS
In the future, as more pharmaceuticals become available to treat diabetes, and as combination therapy becomes more common practice for both T1D and T2D, the potential for these newer approaches in diabetes management to impact musculoskeletal health will require careful and ongoing evaluation. As an endpoint for fracture risk assessment, it is acknowledged that BMD measurement is not adequate, and other integrative determinations will be needed. At least, in instances in which an individual with diabetes has a history of fracture, a choice of treatment options should require the clinician to consider using medications with the least risk to musculoskeletal wellbeing. Finally, because a number of pharmaceuticals have been developed that have been shown to impact the musculoskeletal system, it is incumbent that clinicians be well informed about the association of diabetes with increased fracture risk and muscle atrophy, and that they recognize that certain anti-diabetes medications can predispose to musculoskeletal co-morbidities in those with diabetes, despite improving their glycemic control. 
